Please login to the form below

Not currently logged in
Email:
Password:

MedImmune appoints head of research

Yong-Jun Liu to lead R&D at AstraZeneca biologics subsidiary

MedImmune Jong-Jun LiuAstraZeneca (AZ) has strengthened its research team by appointing leading academic Dr Yong-Jun Liu as head of research at its MedImmune subsidiary.

AZ has made of series of pipeline-boosting acquisitions in the past year, but the appointment of Dr Liu is a move to strengthen its existing R&D operations.

Dr Liu joins the company after an extensive career in academia, which most recently saw him serve as VP and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute for Immunology Research.

He also served for a period as chair of the Department of Immunology at the University of Texas.

MedImmune focuses on the development of biologics and will look to benefit from Dr Liu's experience in immunology as it works to develop a portfolio of immunotherapies, including investigational cancer treatments.

Bahija Jallal, executive VP MedImmune, commented on the company's commitment to develop in-house research through strong leadership.

“Scientific leadership is our top priority,” said Jallal. “We are committed to hiring established leaders who will drive our research engine and progress our efforts to deliver valuable medicines to patients.”

18th November 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics